arrow
C

Caroline Caramella

Université Paris-Saclay
H指数:43
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer

EORTC 1417 - REACTION:一项关于依托泊苷联合顺铂/卡铂,并联合或不联合帕博利珠单抗治疗初治广泛期小细胞肺癌的II期研究

2025-10-300
PRE
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

纳入临床试验的可切除III期非小细胞肺癌(NSCLC)定义:由EORTC肺癌组领导的泛欧洲多学科专家小组的临床病例回顾

2025-10-140
PRE
The impact of dual cannabis and tobacco smoking in young patients with lung cancer: results from the prospective “Environment and Lung Cancer” study

年轻肺癌患者中双重吸食大麻和烟草的影响:来自前瞻性“环境与肺癌”研究的结果

CHEST
IF8.6
2025-09-240
PREAI
Detection and severity quantification of pulmonary embolism with 3D CT data using an automated deep learning-based artificial solution
2024-03-015
PRE
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial

肝动脉奥沙利铂联合静脉注射5-氟尿嘧啶和西妥昔单抗一线治疗结直肠癌肝转移: 一项多中心II期试验

2023-12-011
PRE
Detection and quantification of pulmonary embolism with artificial intelligence: The SFR 2022 artificial intelligence data challenge
2023-10-015
PRE
Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation
2022-11-010
OA
Standardised lesion segmentation for imaging biomarker quantitation: a consensus recommendation from ESR and EORTC

用于成像生物标志物定量的标准化病变分割: ESR和EORTC的共识建议

2022-10-0418
OAAI
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC

监测肿瘤生长速率预测免疫检查点抑制剂在晚期NSCLC中的治疗结果

2022-02-123
OAAI
Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper
2022-01-1021
OAAI
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy
2021-03-0153
PREAI